INAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...

In8bio Inc. has unveiled INB-600, its next-generation γδ T-cell-based T-cell engager (TCE) platform designed to address one of the shortcomings of current existing γδ TCEs, specifically insufficient ...

Impressive results have been achieved by adoptively transferring T-cells expressing CD19-specific CARs with binding domains from murine mAbs to treat B-cell malignancies. T-cell mediated immune ...

Introduced INB-619, a proprietary next generation gamma-delta TCE targeting CD19 for potential use in oncology and autoimmune ...

designed to overcome the limitations of current γδ TCE therapies, which often fail due to inadequate effector cell numbers. The first candidate from this platform, INB-619, targets CD19 ...

The platform’s first candidate, INB-619, targets CD19, a key marker broadly found ... side effects limiting CAR-T and traditional CD3-TCE adoption in autoimmune indications.

which has been a major challenge in previous Gamma-Delta TCE approaches. The first candidate from this platform, INB-619 targets CD19, a marker found on B cells involved in leukemias, lymphomas ...

CDR-Life today announced the expansion of its product portfolio with the nomination of CDR111 as a new clinical candidate for autoimmune diseases along with upcoming posters highlighting the company's ...

Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells ...

a proprietary next generation gamma-delta TCE targeting CD19 for potential use in oncology and autoimmune diseases (March 2025) Demonstrated potent B-cell depletion and sustained gamma-delta T ...